Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

CURATECH PHARMA PVT.LTD.

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000619 42 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx42product presentations
G21generic molecules
DF4dosage-form groups
TA5therapeutic areas
PKR42current price records
REG37registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage93%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixCURATECH PHARMA PVT.LTD.Share of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/curatech-pharma-pvt-ltdGenerated 10 Aug 2026Anti-infectives32 · 76%Vitamins, minerals & nutrition3 · 7%Respiratory & allergy3 · 7%Cardiovascular2 · 5%Gastrointestinal & hepatology2 · 5%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioCURATECH PHARMA PVT.LTD.Distribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/curatech-pharma-pvt-ltdGenerated 10 Aug 202642presentationsTablet24 · 57%Capsule11 · 26%Injection5 · 12%Suspension2 · 5%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionCURATECH PHARMA PVT.LTD.Current company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/curatech-pharma-pvt-ltdGenerated 10 Aug 202639comparable productsBelow market median18 · 46%Near market median19 · 49%Above market median2 · 5%Company median price position-4.9%Lowest-price equivalents1Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsCURATECH PHARMA PVT.LTD.Companies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/curatech-pharma-pvt-ltdGenerated 10 Aug 2026Macter International Limited18 shared86% overlapNabiqasim Industries (Pvt) Ltd.,17 shared81% overlapBio-Labs(Pvt) Ltd17 shared81% overlapNeutro Pharma (Pvt.) Ltd.,17 shared81% overlapS.J & G. Fazul Ellahie (pvt) limite…17 shared81% overlapAllmed (Pvt.) Ltd17 shared81% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives32 products · 76%
Vitamins, minerals & nutrition3 products · 7%
Respiratory & allergy3 products · 7%
Cardiovascular2 products · 5%
Gastrointestinal & hepatology2 products · 5%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antimalarials8 products · 19%
Third-generation cephalosporins6 products · 14%
Fluoroquinolone antibacterials5 products · 12%
Macrolide antibacterials4 products · 10%
Antifungals3 products · 7%
Vitamins / minerals / hematinics3 products · 7%
Antihistamines3 products · 7%
Beta blockers2 products · 5%
Formulation footprint

Dosage forms

Tablet24 products
Capsule11 products
Injection5 products
Suspension2 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 ZicureAzithromycin 4presentations 250 mg, 500 mg · Capsule, Tablet #2 CuraspanCefixime 3presentations 100 mg/5 mL, 200 mg/5 mL, 400 mg · Suspension, Capsule #3 CuraxoneCeftriaxone 3presentations 1 g, 250 mg, 500 mg · Injection #4 FexozinFexofenadine 3presentations 120 mg, 180 mg, 60 mg · Tablet, Capsule #5 CipracinCiprofloxacin 2presentations 250 mg, 500 mg · Tablet #6 CurafloxinLevofloxacin 2presentations 250 mg, 500 mg · Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median1846% of comparable products
Near market median19within ±5% of median
Above market median25% of comparable products
Lowest-price equivalents1ties included
Company median price position -4.9% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Curaqutol 250 mgChloroquine · Tablet · 500's PKR 1.14/tablet-26.7% vs market median Zicure 250 mgAzithromycin · Tablet · 6's PKR 35.32/tablet-24.7% vs market median Zicure 500 mgAzithromycin · Tablet · 6's PKR 64.75/tablet-23.7% vs market median Curaon 8 mgOndansetron · Tablet · 10's PKR 129.06/tablet-22.6% vs market median Techmox 400 mgMoxifloxacin · Tablet · 5's PKR 142.56/tablet-21.1% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Macter International Limited248 products · 91 generics 18shared generics Nabiqasim Industries (Pvt) Ltd.,362 products · 118 generics 17shared generics Bio-Labs(Pvt) Ltd234 products · 82 generics 17shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 17shared generics S.J & G. Fazul Ellahie (pvt) limited.193 products · 68 generics 17shared generics Allmed (Pvt.) Ltd82 products · 48 generics 17shared generics
Regulatory & price activity

Observed database signals

Registration numbers37
Price-history records46
Products with price history4
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date27 Jul 2026
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

8 results
Intelligence filter: Drug classAntimalarials Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Curaqutol Chloroquine 250 mg Tablet 500's 111910 PKR 569.93 PKR 1.14/tablet 27% below median
Curaqutol-H Hydroxychloroquine 200 mg Tablet 50's 111909 PKR 594.11 PKR 11.88/tablet 18% below median
Curaqutol-H Hydroxychloroquine 200 mg Tablet 30's 111909 PKR 356.47 PKR 11.88/tablet 18% below median
Melather Artemether + Lumefantrine 20 mg + 120 mg Tablet 1x16's 048068 PKR 590.91 PKR 36.93/tablet Near median
Melather Artemether + Lumefantrine 20 mg + 120 mg Tablet 12x8's 048068 PKR 3,261.07 PKR 33.97/tablet 13% below median
Melather DS Artemether + Lumefantrine 40 mg + 240 mg Tablet 1x8's 049467 PKR 487.50 PKR 60.94/tablet Near median
Melather DS Plus Artemether + Lumefantrine 80 mg + 480 mg Tablet 6's 062613 PKR 579.83 PKR 96.64/tablet 11% below median
Melather DS Plus Artemether + Lumefantrine 80 mg + 480 mg Tablet 4's 062613 PKR 406.24 PKR 101.56/tablet 7% below median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.